OMass Therapeutics employs a unique platform that integrates proprietary biochemistry, native mass spectrometry, and custom chemistry to explore the interactions of drug targets within their native biological ecosystems. This approach allows the company to study membrane proteins and intracellular complexes, such as Solute Carriers, GPCRs, and Inflammasomes, in a way that preserves the biological relevance of these targets. By maintaining the fidelity of the native environment while utilizing cell-free precision, OMass can accurately measure the physical interactions that drive biological processes, thereby enhancing the drug discovery process.

The company’s pipeline focuses on developing novel small molecules aimed at treating immunological and orphan diseases, with a particular emphasis on targets that exhibit low translation risk. Their research includes first-in-class inhibitors for various conditions, such as lupus and inflammatory bowel disease, and aims to optimize receptor residency time to improve therapeutic efficacy. OMass's innovative approach not only facilitates the identification of effective drug candidates but also allows for the exploration of complex biological interactions, ultimately leading to more targeted and effective treatments.

United Kingdom

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.

OMass Therapeutics

Company Details